Catalyst Biosciences Reports Third Quarter 2017 Operating & Financial Results and Provides Corporate Update
-- Phase 1/2 trial of Factor IX CB 2679d is advancing with interim results expected by year-end -- -- Phase 2 trial of Factor FVIIa marzeptacog alfa (activated) on track for initiation by year-end-- SOUTH SAN FRANCISCO, Calif., Nov. 02, 2017 (GLOBE …